Arcus Biosciences (RCUS) Q1 2024 Earnings
RCUS·Reported May 8, 2024·After market close
Arcus Biosciences reported Q1 2024 revenue of $145.0M, beat analyst consensus of $35.6M by $109.4M. Diluted EPS came in at $-0.05, beat the $-0.97 consensus by $0.92.
Revenue
$145.0Mbeat by $109.4M
Consensus: $35.6MDiluted EPS
$-0.05beat by $0.92
Consensus: $-0.97
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Arcus Biosciences's Q1 2024 earnings report.
Arcus Biosciences (RCUS) reported Q1 2024 earnings on May 8, 2024 after market close.
Arcus Biosciences reported revenue of $145.0M and diluted EPS of $-0.05 for Q1 2024.
Revenue beat the consensus estimate of $35.6M by $109.4M. EPS beat the consensus estimate of $-0.97 by $0.92.
You can read the 10-Q periodic report (0001724521-24-000092) directly on SEC EDGAR. The filing index links above go to sec.gov.